Redwood AI has been anything but quiet in May. The company kicked off a collaboration with Vancouver-based Resilience Biosciences, locked down federal funding for a chemical safety project, and — most ambitiously — signed a non-binding letter of intent to acquire Quantum.IQ, a Canadian specialist in post-quantum cryptography. The all-stock deal marks the firm’s boldest pivot yet, moving from AI-powered drug discovery into the race to secure data against future quantum computers.
Quantum.IQ has built an AI-driven platform that scans existing IT infrastructure for cryptographic vulnerabilities and guides organisations through the migration to post-quantum standards — from initial inventory to continuous monitoring. Redwood AI is targeting three primary customer groups with the technology: government agencies, defence organisations and large financial institutions. All are sectors where data must remain secure for decades and where the eventual switch to quantum-resistant encryption is seen as inevitable.
Under the terms outlined in the letter of intent, the acquisition will be paid entirely in shares. Sellers will receive up to 14 million Redwood common shares, split into 7 million at closing and a further 7 million tied to the achievement of specific milestones. The shares will be released from an escrow arrangement over 24 months, designed to lock in long-term commitment. The deal remains conditional: a formal due diligence process, the signing of a definitive purchase agreement, and approval from the Canadian Securities Exchange are all required before it can proceed.
Should investors sell immediately? Or is it worth buying Redwood AI?
Quantum.IQ is led by CEO Kevin O’Neill, a veteran with more than 35 years of experience in technology investments and company building. He previously co-founded Teleo Communications, which was sold to Microsoft; Workfire Technologies, acquired by Packeteer; and Xtract AI Technologies, which Patriot One bought. For Redwood, artificial intelligence serves as the connective tissue — the same core competency that once simulated molecules for drug discovery will now be applied to cryptographic analysis.
Elsewhere in May, Redwood inked a partnership with Resilience Biosciences, a clinical-stage biopharma firm, under which Redwood’s AI platform will be deployed to accelerate drug research. At the same time, a subsidiary received up to 240,000 CAD from the National Research Council of Canada for the Q-SAFE project, which aims to develop quantum-optimised methods for classifying hazardous chemicals.
The flurry of activity underscores a company trying to remake itself. Whether Redwood can successfully juggle chemistry, biopharma and cybersecurity — all while integrating an acquisition that is still far from certain — will determine whether this May is remembered as a turning point or just a busy month.
Ad
Redwood AI Stock: Buy or Sell?! New Redwood AI Analysis from May 29 delivers the answer:
The latest Redwood AI figures speak for themselves: Urgent action needed for Redwood AI investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from May 29.
Redwood AI: Buy or sell? Read more here...
